Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma

Next Previous
X
Search
Trial Profile

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzupacap sarotalocan (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Aura Biosciences

    • Most Recent Events

    • 01 Sep 2022 According to Aura Biosciences media release, interim safety data from phase II trial and final safety will be presented in 22nd EURETINA Congress in 1st-4th September.
    • 11 Aug 2022 According to an Aura Biosciences media release, results from this study were presented at the International Society of Ocular Oncology (ISOO) 2022 Bi-Annual Meeting.
    • 22 Jun 2022 Results from a retrospective analysis of this trial presented in an Aura Biosciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top